Previous 10 | Next 10 |
Antares Pharma (NASDAQ:ATRS) is scheduled to announce Q4 earnings results on Thursday, Mar. 3, before market open. The consensus EPS estimate is $0.01 and the consensus revenue estimate is $47.19M (+7% Y/Y). Over the last 2 years, ATRS has beaten EPS estimates 75% of the time and has bea...
EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at ...
EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the ...
The FDA has accepted a New Drug Application for the oral testosterone replacement therapy ("TRT") Tlando from Antares Pharma (NYSE:ATR). The new action date is March 28. Tlando was granted tentative approval as a twice daily treatment. Previously, the FDA determined that Tlando met efficacy a...
EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) ...
EWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for ATRS-1902 for adrenal...
EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Mr. Richardson will be responsible for A...
EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support the advancement of the A...
HALIFAX, Nova Scotia, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announced today the appointment of Mr. Thomas Bergmann to the board effective immediately. Mr. Bergmann is the former CEO and Member of the Board of the US based pharmaceutical company Ma...
EWING, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the divestiture of OTREXUP ® (methotrexate) injection for the treatment of rheumatoid arthritis to a subsidiary of A...
News, Short Squeeze, Breakout and More Instantly...
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...